Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245716
Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (â€œBMSâ€), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.
IPSCIO Record ID: 245715
Targeting the CD3 receptor is a well-validated approach to modulating T-cell response and achieving immunosuppression. Foralumab is a phase II asset with potential application in a wide range of autoimmune and inflammatory diseases, such as multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
The Licensee will develop antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer using CD3 receptor monoclonal antibodies.
IPSCIO Record ID: 289246
Licensor has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies that are highly potent compared with Remicade and Humira in in-vitro assays.
Licensor will provide Humanized Rabbit anti-TNFalpha monoclonal antibodies to Licensee.